



## SUPPLEMENTAL FIGURES S1-S4

**Supplementary Fig. S1.**




**Supplementary Fig. S1. *TBK1* knockdown increases cell migration.** Phase-contrast microscopy image of an *in vitro* wound healing assay at 0 and 16 hr after wounding in *TBK1*-knockdown breast cancer cells. Original magnification, 100×.

**Supplementary Fig. S2.**




**Supplementary Fig. S2. TBK1 knockdown increases cell invasion.** Transwell invasion assays of TBK1-knockdowned breast cancer cells. Cell invasion was assayed in transwell coated with Matrigel. After 24 hr, cells crossed the Matrigel-coated filter were fixed, stained with toluidine blue and counted. Representative pictures of the bottom surface are shown. Original magnification, 100 $\times$ .

**Supplementary Fig. S3.**



**Supplementary Fig. S3. *TBK1* knockdown did not inhibit the expression of ER $\alpha$  proteins via the proteasomal degradation pathway.** Immunoblot analysis of ER $\alpha$  and TBK1 in MCF-7 breast cancer cells expressing *TBK1*-specific shRNA after treatment with the proteosome inhibitor MG132. Cells were treated with or without 10  $\mu$ M MG132 for 4 hr.

**Supplementary Fig. S4.**



**Supplementary Fig. S4. TBK1 knockdown induces phosphorylation of AKT in ER $\alpha$ -positive breast cancer cells.** Analysis of proteome profiler in 46 human phosphor-protein kinase array assessed in lysates from ZR-75B breast cancer cell lines expressing *TBK1*-specific shRNA.

**SUPPLEMENTAL TABLE 1 and TABLE 2****Supplementary Table 1. ER $\alpha$  promoter-specific primer pairs.**

Regions	primer sequence
-3,219/-2,951	Forward: 5'-AGCTGAGAGCATGGCAATT-3' Reverse: 5'-ATCTGCCACCCCAGATGATA-3'
-2,208/-1,907	Forward: 5'-GCACGTGTGTTCCCATAGTG-3' Reverse: 5'-TCCAACCAGAGGTTGATTGA-3'
-1,834/-1,534	Forward: 5'-TGCCAGTACTAACATGACTTG-3' Reverse: 5'-TTGATATTGCGTTGCATTCCA-3'
-1,258/-1,032	Forward: 5'-TTTCGCTTCAAAACACTTGA-3' Reverse: 5'-TCCAGAATACATAGAGCAGGACA-3'
-624/-251	Forward: 5'-TGATTTACAGCCCCTTGC-3' Reverse: 5'-GACAGGCATGTGGAGTTGG-3'
-350/-111	Forward: 5'-CTTGCCCCCTGCTTTAGTT-3' Reverse: 5'-CCAGGCCGAATCTAACTTT-3'

**Supplementary Table 2. Sequence of putative FOXO3A binding site in the 4-kb ER $\alpha$  promoter.**

Regions	Putative FOXO3A binding sequence		
-3,219/-2,951	$-3,197$ CTTAGAAC $^{-3,190}$	$-3,152$ CAGGTAAG $^{-3,145}$	
-2,208/-1,907	$-2,074$ CTTAATCT $^{-2,067}$	$-2,020$ CTTACCTC $^{-2,013}$	$-1,992$ CTTAAACT $^{-1,985}$
-1,834/-1,534	$-1,746$ ATTATAAG $^{-1,739}$	$-1,631$ ATACTAAG $^{-1,624}$	
-1,258/-1,032	$-1,170$ CTTACAGA $^{-1,163}$	$-1,127$ TGTGTAAG $^{-1,120}$	
-624/-251	$-587$ CTTAGTGT $^{-580}$	$-552$ CTTAAAAA $^{-545}$	$-391$ TGAGTAAG $^{-384}$
-350/-111	$-149$ CTTAATGG $^{-142}$	$-139$ GTGCTAAG $^{-132}$	